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Background: In November 2015, Liu and colleagues described for the first time a plasmid mediated colistin resistance in 
Escherichia coli from animal and human sources, this mechanism was attributed to mcr-1 gene. The mcr-1 gene was further 
described in several countries mostly in E. coli associated to several different plasmid backbones. In view of the concerning spread 
of antibiotic resistance, the aim of this study was to screen clinical isolates of Enterobacteriaceae for the presence of the mcr-1 
gene. Methods: We retrospectively screened a total of 2136 clinical isolates of carbapenem-resistant Enterobacteriaceae (CRE) 
obtained between 2013 and 2016 recovered during a surveillance study in southern Brazil. The mcr-1 gene was screened in pools 
of suspension of 20 isolates. DNA was extracted from the pools and submitted to PCR using specific primers. Isolates from the pool 
with positive result were tested individually for PCR. Conjugation experiments were performed using the E. coli J53 as a receptor 
strain and the susceptibility profile was evaluated by Etest (carbapenem) and by broth microdilution (colistin). Whole genome 
sequencing (WGS) was carried out in a MiSeqTM platform (Illumina, Inc). Results: We were able to identify the mcr-1 gene in only 
one E. coli clinical isolate which was also positive for the blaKPC-2 gene (isolate number 3431F). This isolate was obtained in 
2014, from a rectal swab of a patient at the emergence room of a hospital. The isolate 3431F presented minimal inhibitory 
concentration (MIC) of 4 µg/ml and 32 µg/ml, of colistin and meropenem, respectively. Conjugation experiments demonstrated that 
mcr-1 and the blaKPC-2 were present in different plasmids and that both plasmids were successfully transferred to E. coli J53. The 
in silico analyses of the WGS data indicated that the 3431F isolate belongs to the ST744 and detailed analysis of the WGS also 
indicated that the blaKPC-2 was located in an IncFIB plasmid and the mcr-1 in a IncX4. Conclusion: The prevalence of the mcr-1 
gene among clinical isolates of CRE was very low in southern Brazil. Nevertheless, since polymyxins are considered as last resort 
antibiotics for the treatment of infections caused by CRE, the vigilance of isolates harboring carbapenem and colistin resistance is 
of great concern to public health. To the best of our knowledge, this is the first description of a clinical isolate harboring both 
blaKPC-2 and mcr-1 genes in Latin-America. Palavras-chaves: polymyxin, carbapenem, resistance genes 
